Highlights
June 25, 2020
The authors concluded that there is little evidence that either regimen improves overall survival compared to the historical pattern of treatment. SWOG S1505 is a prospective, […]
June 24, 2020
Results indicate an overall response rate of 36.4% and a safety profile consistent with the disease Therapeutic options for patients with advanced melanoma, especially those who […]
June 22, 2020
Updated data from the KEYNOTE-426 trial was presented at the ASCO 2020 Virtual Annual Meeting Previous results from KEYNOTE-426, a phase III randomized, open-label trial (NCT02853331), […]
June 19, 2020
Recent data suggest that the tumor suppressor gene ARID1A is associated with high antitumor immunity and may be a predictive biomarker of response to immunotherapy in […]
June 16, 2020
5FU / LV plus panitumumab for up to 12 cycles, followed by maintenance of panitumumab until disease progression may be a reasonable option in elderly patients […]
June 15, 2020
Phase II trials evaluated the activity of tipifarnib in squamous carcinomas, tumors of the thyroid and salivary glands, urothelial carcinomas, among others HRAS is an overexpressed […]
June 9, 2020
Results presented at ASCO 2020 evaluated pembrolizumab versus brentuzimab vedotin With clinically significant results, a phase III KEYNOTE-204 trial, presented at the ASCO 2020 Virtual Annual […]